Breast cancer scoring based on a multiplexed profiling of soluble and cell-associated (immune) markers facilitates the prediction of pembrolizumab therapy

Abstract Background The immune checkpoint targeting is nowadays an integral part of cancer therapies. However, only a minority of patients experience long-term benefits. Thus, the identification of predictive biomarkers contributing to therapy response is urgently needed. Methods Here, we analyzed d...

Descripció completa

Dades bibliogràfiques

Autors principals:	Verena Schweihofer, Christina Bruss, Stephan Seitz, Gunther Glehr, Madeleine Hetterich, Florian Weber, Maria Hatzipanagiotou, Miriam Fernández-Pacheco Álvarez, Olaf Ortmann, Gero Brockhoff, Richard J. Bauer, Anja Kathrin Wege
Format:	Artigo
Idioma:	Inglês
Publicat:	BMC 2025-03-01
Col·lecció:	Cancer Cell International
Matèries:	Checkpoint expression Checkpoint secretion Soluble factors Checkpoint therapy Breast cancer (BC) Tumor phenotype
Accés en línia:	https://doi.org/10.1186/s12935-025-03729-7
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!